TY - JOUR
T1 - Monoamine oxidase type B inhibitors in early Parkinson’s disease
T2 - meta-analysis of 17 randomised trials involving 3525 patients
AU - Ives, N J
AU - Stowe, R L
AU - Marro, J.
AU - Counsell, Carl Edward
AU - MacLeod, Angus
AU - Clarke, C. E.
AU - Gray, R
AU - Wheatley, K.
PY - 2004/9/9
Y1 - 2004/9/9
N2 - Objective To quanti, more reliably the benefits and risks of monoamine oxidase type B inhibitors (MAOBIs) in early Parkinson's disease.Data sources Searches of the Cochrane Library, Medline, Embase, PubMed, and Web of Science for years 1966-2003, plus major journals in the field, abstract books, and proceedings of meetings, for randomised trials comparing MAOBIs with placebo or levodopa.Data extraction Available data on mortality, motor complications, side effects, treatment compliance, and clinician rated disability (for example, unified Parkinson's disease rating scale) were extracted from 17 trials and combined using standard meta-analytic methods.Results No significant difference in mortality existed between patients on MAOBIs and control patients (odds ratio 1.13, 95% confidence interval 0.94 to 1.34; P=0.2). Patients randomised to MAOBIs had significantly better total scores, motor scores, mid activities of daily living scores on the unified Parkinson's disease rating scale at three months compared with patients taking placebo; they were also less likely to need additional levodopa (0.57, 0.48 to 0.67; P<0.00001) or to develop motor fluctuations (0.75, 0.59 to 0.95; P=0.02). No difference existed between the two groups in the incidence of side effects or withdrawal of patients.Conclusions MAOBIs reduce disability, the need for levodopa, and the incidence of motor fluctuations, without substantial side effects or increased mortality. However, because few trials have compared MAOBIs with other antiparkinsonian drugs, uncertainty remains about the relative benefits and risks of MAOBIs. Further large, long term comparative trials that include patient rated quality of life measures are needed.
AB - Objective To quanti, more reliably the benefits and risks of monoamine oxidase type B inhibitors (MAOBIs) in early Parkinson's disease.Data sources Searches of the Cochrane Library, Medline, Embase, PubMed, and Web of Science for years 1966-2003, plus major journals in the field, abstract books, and proceedings of meetings, for randomised trials comparing MAOBIs with placebo or levodopa.Data extraction Available data on mortality, motor complications, side effects, treatment compliance, and clinician rated disability (for example, unified Parkinson's disease rating scale) were extracted from 17 trials and combined using standard meta-analytic methods.Results No significant difference in mortality existed between patients on MAOBIs and control patients (odds ratio 1.13, 95% confidence interval 0.94 to 1.34; P=0.2). Patients randomised to MAOBIs had significantly better total scores, motor scores, mid activities of daily living scores on the unified Parkinson's disease rating scale at three months compared with patients taking placebo; they were also less likely to need additional levodopa (0.57, 0.48 to 0.67; P<0.00001) or to develop motor fluctuations (0.75, 0.59 to 0.95; P=0.02). No difference existed between the two groups in the incidence of side effects or withdrawal of patients.Conclusions MAOBIs reduce disability, the need for levodopa, and the incidence of motor fluctuations, without substantial side effects or increased mortality. However, because few trials have compared MAOBIs with other antiparkinsonian drugs, uncertainty remains about the relative benefits and risks of MAOBIs. Further large, long term comparative trials that include patient rated quality of life measures are needed.
KW - INITIAL TREATMENT
KW - SELEGILINE
KW - LEVODOPA
KW - DEPRENYL
KW - PROGRESSION
KW - MORTALITY
KW - DISABILITY
KW - MULTICENTER
KW - RELEVANT
KW - THERAPY
U2 - 10.1136/bmj.38184.606169.AE
DO - 10.1136/bmj.38184.606169.AE
M3 - Article
SN - 0959-8146
VL - 329
SP - 593
EP - 596
JO - British Medical Journal
JF - British Medical Journal
IS - 7466
ER -